An acute exacerbation of COPD (AECOPD) is an acute worsening of respiratory symptoms over days (up to 14 days), characterized by increased dyspnea and/or cough and sputum, often accompanied by tachypnea and tachycardia. It is most commonly triggered by viral or bacterial respiratory infections and environmental pollutants. Approximately 25% of patients hospitalized for AECOPD die within 1 year, and close to 70% of readmissions result from decompensation of comorbidities rather than COPD itself. [1-2]
1. History
- Key HPI questions: Onset and duration of worsening dyspnea, cough, sputum volume and color (especially purulence), wheeze, chest tightness
- Symptom characterization: Quantify dyspnea severity (VAS 0–10); compare to baseline functional status; ask about exercise tolerance and ability to perform ADLs [1]
- Timing/triggers: Recent URI, sick contacts, cold/heat exposure, air pollution, wildfire smoke, medication non-adherence, recent steroid taper [3]
- Progression: Gradual over days (typical AECOPD) vs. sudden onset (consider PE, pneumothorax)
- Associated symptoms: Fever, hemoptysis, chest pain, leg swelling, orthopnea, weight gain
- Important negatives: No pleuritic chest pain, no unilateral leg swelling, no syncope, no recent immobilization/surgery
2. Alarm Features
- Dyspnea or tachypnea at rest unrelieved by bronchodilators [4]
- Altered mental status (confusion, somnolence — suggests hypercapnia/ventilatory failure) [3]
- Accessory muscle use, tripoding, inability to speak in full sentences
- SpO₂ <88%, cyanosis
- Hemodynamic instability (hypotension, tachycardia >120 bpm)
- New-onset chest pain or hemoptysis (consider PE, MI, pneumothorax)
- Fever with localized chest findings (pneumonia) [4]
- Increasing lower-extremity edema (acute heart failure, cor pulmonale)
3. Medications
Acute treatment (the "Big 3"): [3][5]
- Bronchodilators: Albuterol 2.5 mg nebulized q20 min × 3, then q1–4h; add ipratropium 0.5 mg nebulized if limited response. MDI with spacer is equally effective in less sick patients [3]
- Systemic corticosteroids: Prednisone 40 mg PO daily × 5 days (equally effective as longer courses, with fewer side effects) [3][5]
- Antibiotics (when indicated): 5-day course — first-line: amoxicillin/clavulanate, azithromycin, or doxycycline; reserve fluoroquinolones for repeated exacerbations or suspected resistance [4][6-7]
Contraindicated/avoid
- Methylxanthines (theophylline/aminophylline) — not recommended due to significant side effects and no proven benefit [3]
- Avoid excessive oxygen (target SpO₂ 88–92% in COPD to prevent CO₂ retention) [8]
- Sedatives, opioids, and benzodiazepines should be used with extreme caution
Medication cautions
- Short steroid bursts still carry risk of pneumonia, sepsis, hyperglycemia, and psychosis (especially in elderly) [3]
- Blood eosinophil-guided steroid use is emerging — steroids may be safely withheld in patients with low eosinophils in primary care settings [3]
4. Diet
- Acute phase: Small, frequent meals to reduce diaphragmatic splinting; avoid large meals that worsen dyspnea
- Hydration: Adequate hydration to thin secretions (unless fluid-restricted for heart failure)
- Long-term: Mediterranean-style diets rich in antioxidants, fruits, vegetables, and fiber are associated with better lung health outcomes [9]
- Nutritional status: Malnutrition is common in advanced COPD and is an independent risk factor for poor outcomes; assess BMI and consider nutritional supplementation [10]
5. Review of Systems
- Pulmonary: Dyspnea severity, cough character, sputum volume/color, wheeze, hemoptysis
- Cardiovascular: Chest pain, palpitations, orthopnea, PND, leg edema (heart failure, PE, MI are common mimics) [3]
- Infectious: Fever, chills, myalgias, recent URI symptoms
- Psychiatric: Anxiety, panic (can mimic or worsen dyspnea); depression (common comorbidity)
- GI: GERD symptoms (risk factor for exacerbations) [3]
- Musculoskeletal: Deconditioning, muscle wasting
6. Collateral History and Family History
- Collateral: Baseline functional status, home oxygen use, prior intubations/ICU admissions, medication adherence, inhaler technique, caregiver support at home
- Family history: Alpha-1 antitrypsin deficiency (especially if early-onset COPD or minimal smoking history)
- Social context: Smoking status (current vs. former, pack-years), biomass fuel exposure, occupational exposures, housing conditions (mold, pollution), ability to access medications and follow-up
7. Risk Factors
- Strongest predictor: History of prior exacerbations (≥2/year defines the "frequent exacerbator" phenotype) [3][11]
- Severe airflow limitation (low FEV₁) [3]
- Active smoking or ongoing pollutant exposure [3]
- Comorbidities: heart failure, coronary artery disease, GERD, anxiety/depression, bronchiectasis [2-3]
- Poor nutritional status, low BMI [10]
- Female sex [12]
- Winter season, cold temperatures, influenza circulation [3][12]
- Non-adherence to maintenance inhalers
- Elevated blood eosinophils (associated with steroid-responsive exacerbations) [3]
8. Differential Diagnosis
Per the 2026 GOLD guidelines, the following conditions can mimic or worsen AECOPD and must be systematically excluded: [2-3]
Most frequent mimics
- Pneumonia — fever, focal consolidation on CXR, elevated CRP/procalcitonin
- Acute heart failure — orthopnea, bilateral edema, elevated BNP/NT-proBNP, pulmonary edema on CXR
- Pulmonary embolism — sudden-onset dyspnea, pleuritic chest pain, hemoptysis, DVT risk factors, elevated D-dimer
- Acute coronary syndrome / arrhythmia — chest pain, palpitations, ECG changes, elevated troponin
- Acute viral/bacterial bronchitis — overlaps significantly with AECOPD
Less frequent
- Pneumothorax — sudden pleuritic pain, absent breath sounds, hyperresonance
- Interstitial lung disease exacerbation
- Anxiety/panic attack — diagnosis of exclusion
Pearl: ~15% of patients admitted with a diagnosis of AECOPD do not actually have AECOPD after adjudication, and ~28% have AECOPD with a concurrent condition contributing to dyspnea. [13]
9. Past Medical History
- Prior COPD diagnosis, baseline FEV₁, GOLD stage
- Prior exacerbation frequency (most important predictor of future events) [3]
- History of intubation or ICU admission
- Home oxygen use, home NIV/CPAP
- Comorbidities: CHF, CAD, atrial fibrillation, diabetes, CKD, OSA, bronchiectasis
- Vaccination status: influenza, pneumococcal, COVID-19, RSV
- Surgical history: prior lung surgery, lung volume reduction
10. Physical Exam
Vital signs
Focused exam
- Respiratory: Accessory muscle use, pursed-lip breathing, prolonged expiratory phase, diffuse wheezing, decreased breath sounds, barrel chest. Focal crackles → pneumonia; absent breath sounds unilaterally → pneumothorax
- Cardiovascular: JVD, peripheral edema, S3 gallop (heart failure); irregular rhythm (atrial fibrillation)
- Mental status: Confusion, somnolence → hypercapnic encephalopathy (ventilatory failure)
- Extremities: Cyanosis, clubbing (consider bronchiectasis, lung cancer), calf asymmetry (DVT)
11. Lab Studies
Recommended in ED/hospital setting: [1][14-15]
- ABG/VBG: Assess for hypoxemia (PaO₂ ≤60 mmHg), hypercapnia (PaCO₂ >45 mmHg), and acidosis (pH <7.35) — gold standard for severity classification [3]
- CBC: Leukocytosis (infection), eosinophilia (may guide steroid use), anemia
- BMP: Electrolytes, renal function (BUN ≥25 is a BAP-65 risk factor)
- CRP: Recommended by GOLD; CRP ≥10 mg/L suggests moderate/severe exacerbation; CRP >11.5 mg/L has 91% sensitivity for consolidation on CT [1][16]
- BNP/NT-proBNP: Rule out heart failure as mimic or co-contributor [3]
- Troponin: If ACS or PE suspected [3]
- D-dimer: If PE is clinically suspected
- Procalcitonin: May help guide antibiotic decisions (bacterial vs. viral)
- Blood eosinophils: Emerging role in guiding corticosteroid therapy [3]
- Sputum culture: Not routinely useful due to chronic colonization; consider in severe exacerbations or treatment failure [4]
12. Imaging
- Chest X-ray (first-line): Obtain in all moderate/severe exacerbations to rule out pneumonia, pneumothorax, pleural effusion, pulmonary edema [3][15]
- CT chest: Not routine; indicated if concern for PE (CTA), suspected malignancy, or recurrent exacerbations (evaluate for bronchiectasis, emphysema) [3]
- Point-of-care ultrasound: Useful for rapid assessment of pneumothorax, pleural effusion, B-lines (pulmonary edema), cardiac function, and IVC [14]
- Imaging unnecessary: Mild exacerbations managed in the outpatient setting with clear clinical picture
13. Special Tests
- BAP-65 Score: Risk-stratifies in-hospital mortality and need for mechanical ventilation in AECOPD patients >40 years (uses BUN, altered mental status, pulse, and age)[supported calculator]
- Rome Severity Classification: Uses dyspnea VAS, RR, HR, SpO₂, CRP, and ABG to classify mild/moderate/severe [1][3]
- GOLD COPD Criteria: For stable-state classification (not during acute exacerbation) to guide long-term therapy[supported calculator]
- End-tidal CO₂ (ETCO₂): Waveform analysis can help assess bronchospasm severity and CO₂ retention [14]
- Viral respiratory panel: Nasal swab to identify viral triggers (rhinovirus, influenza, RSV) [3]
14. ECG
- Indications: Obtain in all moderate/severe exacerbations presenting to the ED [15]
- Expected findings: Sinus tachycardia, right axis deviation, P-pulmonale (peaked P waves in II, III, aVF), low voltage, poor R-wave progression
- Dangerous patterns to recognize:
- Atrial fibrillation/flutter — common comorbidity and exacerbation mimic [3]
- Right heart strain (S1Q3T3, RBBB, RV strain pattern) → consider PE
- ST changes/T-wave inversions → ACS
- Multifocal atrial tachycardia (MAT) — classically associated with severe COPD/cor pulmonale
15. Assessment
Severity stratification (Rome Classification): [3]
- Typical presentation: Gradual worsening of dyspnea, cough, and sputum over days with diffuse wheezing
- Atypical presentations: Isolated confusion in elderly (hypercapnia), chest pain (consider PE/ACS), isolated edema (cor pulmonale/CHF)
- Complications: Respiratory failure, pneumothorax, arrhythmia, VTE, secondary pneumonia, death
- Approximately 25% die within 1 year and 65% within 5 years of hospitalization for AECOPD [2]
16. Treatment Plan
Initial stabilization (ED)
- Controlled oxygen: Target SpO₂ 88–92% via Venturi mask or nasal cannula; avoid high-flow uncontrolled O₂ (risk of CO₂ narcosis) [8]
- Bronchodilators: Albuterol 2.5 mg + ipratropium 0.5 mg nebulized (use air-driven nebulizer, not oxygen-driven, to avoid worsening hypercapnia) [3]
- Systemic steroids: Prednisone 40 mg PO (or IV methylprednisolone if unable to take PO) × 5 days [3]
- Antibiotics: If purulent sputum, prior positive sputum culture, or requiring ventilatory support — amoxicillin/clavulanate, azithromycin, or doxycycline × 5 days [3][6]
Respiratory support escalation: [3][17]
- HFNC — first-line for acute hypoxemic respiratory failure; also emerging as option for hypercapnic failure
- NIV (BiPAP) — first-line for hypercapnic respiratory failure (pH <7.35, PaCO₂ >45); typical settings: IPAP 12–16 cm H₂O, EPAP 4 cm H₂O; success rate 80–85% [3][8]
- Intubation/mechanical ventilation — if NIV fails, severe acidosis (pH ≤7.25), altered mental status, hemodynamic instability
Inpatient considerations: [3]
- VTE prophylaxis (LMWH or UFH)
- Monitor fluid balance
- Continue or initiate long-acting bronchodilators (LABA + LAMA) when stable
- Identify and treat comorbidities (heart failure, arrhythmias, PE)
17. Disposition
Admission criteria: [3-4]
- New or worsening hypoxemia or hypercapnia
- Persistent dyspnea/tachypnea after initial bronchodilator and steroid therapy
- Respiratory acidosis (pH <7.35)
- Altered mental status
- Accessory muscle use, overt respiratory distress
- Need for NIV or mechanical ventilation
- Significant comorbidities (heart failure, arrhythmia)
- Inadequate home support, frailty, elderly
ICU admission
- Ventilatory failure (PaCO₂ >60, pH ≤7.25)
- Hemodynamic instability
- Need for intubation
- Failure to improve on NIV
Discharge criteria: [3]
- Able to use inhaler correctly and manage at home
- SABA use ≤ q4h
- Able to ambulate (if previously ambulatory)
- Able to eat and sleep without frequent dyspnea
- Clinically stable for 12–24 hours
- ABG stable (if previously abnormal)
- Supplemental oxygen needs assessed
Observation: Consider for patients with moderate exacerbations who respond partially to ED treatment but have borderline stability or social concerns
Specialist consultation triggers: Pulmonology for recurrent exacerbations, diagnostic uncertainty, need for advanced therapies, or consideration of lung volume reduction/transplant
18. Follow Up / Return Precautions
Follow-up timing: [3-4]
- Early follow-up: <4 weeks post-discharge (reduces readmission risk)
- Late follow-up: 12–16 weeks — spirometry, reassess symptoms (CAT/mMRC), oxygen needs, comorbidities
- Contact within 48 hours of ED discharge to verify stability [4]
At discharge, ensure: [3][18]
- Review and optimize maintenance therapy (LABA + LAMA ± ICS based on eosinophils and exacerbation history)
- Reassess inhaler technique
- Smoking cessation counseling
- Vaccination status (influenza, pneumococcal, COVID-19, RSV)
- Pulmonary rehabilitation referral (ideally within 3 weeks)
- Provide written action plan
Return precautions — instruct patients to seek immediate care for:
- Worsening shortness of breath not relieved by rescue inhaler
- Confusion, excessive drowsiness
- Fever >101°F (38.3°C)
- Chest pain
- Coughing up blood
- New or worsening leg swelling
Expected recovery: 4–6 weeks; up to 20% of patients do not return to pre-exacerbation baseline. [3] Readmission rates are 30–50% within 30 days, making close follow-up critical. [3]
References
1. Pocket Guide to COPD Diagnosis, Management, and Prevention: 2026 Report. — Global Initiative for Chronic Obstructive Lung Disease. 2025.
2. Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice. — Celli BR, Fabbri LM, Aaron SD, et al. American Journal of Respiratory and Critical Care Medicine. 2023.
3. 2026 GOLD Report and Pocket Guide: Global Strategy for Prevention, Diagnosis, and Management of COPD – 2026 Report. — Global Initiative for Chronic Obstructive Lung Disease. 2025.
4. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. — Riley CM, Sciurba FC. The Journal of the American Medical Association. 2019.
5. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. — Celli BR, Wedzicha JA. The New England Journal of Medicine. 2019.
6. Antibiotic Courses for Common Infections: Recommendations From the ACP. — Dakkak M, Sabharwal M. American Family Physician. 2022.
7. Management of Chronic Obstructive Pulmonary Disease (COPD) (2021). — Curtis J. Aberle MSN FNP-BC, Nathan L. Boyer MD FCCS, Andrew Buelt DO, et al Department of Veterans Affairs. 2021.
8. High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. — RENOVATE Investigators and the BRICNet Authors, Maia IS, Kawano-Dourado L, et al. The Journal of the American Medical Association. 2025.
9. Nutriepigenomics and Chronic Obstructive Pulmonary Disease: Potential Role of Dietary and Epigenetics Factors in Disease Development and Management. — Marín-Hinojosa C, Eraso CC, Sanchez-Lopez V, et al. The American Journal of Clinical Nutrition. 2021.
10. Analyses of Factors Associated With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Review. — Qian Y, Cai C, Sun M, Lv D, Zhao Y. International Journal of Chronic Obstructive Pulmonary Disease. 2023.
11. Immunostimulants Versus Placebo for Preventing Exacerbations in Adults With Chronic Bronchitis or Chronic Obstructive Pulmonary Disease. — Fraser A, Poole P. The Cochrane Database of Systematic Reviews. 2022.
12. Factors Associated With Chronic Obstructive Pulmonary Disease Exacerbation, Based on Big Data Analysis. — Lee J, Jung HM, Kim SK, et al. Scientific Reports. 2019.
13. Complexity in Clinical Diagnoses of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. — Pratt AJ, Purssell A, Zhang T, et al. BMC Pulmonary Medicine. 2023.
14. Acute Care of Patients With Moderate Respiratory Distress: Recommendations From an American College of Emergency Physicians Expert Panel. — Baugh CW, Neuenschwander JF, Lenox J, et al. The Western Journal of Emergency Medicine. 2025.
15. Standards for the Diagnosis and Treatment of Patients With COPD: A Summary of the ATS/ERS Position Paper. — Celli BR, MacNee W. The European Respiratory Journal. 2004.
16. Phenotyping COPD Exacerbations Using Imaging and Blood-Based Biomarkers. — Alotaibi NM, Chen V, Hollander Z, et al. International Journal of Chronic Obstructive Pulmonary Disease. 2018.
17. Noninvasive Respiratory Support for Adults with Acute Respiratory Failure. — Munshi L, Mancebo J, Brochard LJ. The New England Journal of Medicine. 2022.
18. A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards. — Benetti A, Fiorelli EM, Grassi D, Montano N. International Journal of Chronic Obstructive Pulmonary Disease. 2025.